52 results about "Glucose binding" patented technology

A noninvasive or minimally invasive procedure and system for measuring blood glucose levels is disclosed. A set of photodiodes detects the fluorescence and reflectance of light energy emitted from one or more emitters, such as LEDs, into a patient's skin. In an embodiment, small molecule metabolite reporters (SMMRs) that bind to glucose are introduced to the measurement area to provide more easily detected fluorescence.

A sensor comprises respective acceptor and donor compounds immobilised in or on a matrix including a glucose-binding boronate and a cationic species, whereby the spacing between the acceptor and donor compounds is reduced in the presence of glucose. For example a holographic sensor comprises a glucose-binding boronate and a cationic species held within the sensor.

Disclosed are embodiments that relate to the deployment of a glucose sensor comprising an optical fiber into a physiological fluid, wherein the optical fiber has disposed along a distal region thereof a chemical indicator system comprising a fluorophore and a glucose binding moiety immobilized within a hydrogel, wherein the components of the chemical indicator system are in a dry state before deployment. Also disclosed is a one-point in vivo calibration of the chemical indicator system based on an independently measured glucose concentration.

An on-body sensor (OBS) (5610) having a continuous monitoring (CGM) device is disclosed for use in identifying an analyte, such as glucose in blood or interstitial fluid (ISF), using a biomaterial, such as glucose binding protein (GBP), that is brought into contact with the analyte. The on-body sensor (5610) incorporating the CGM device includes a housing (5625′) which provides protection to the CGM device while providing comfort to a user wearing the device. The OBS also includes an adhesive structure that provides a comfortable, discreet and secure user experience.

The invention relates to isolated polynucleotides encoding functional cellulose synthases and UDP-glucose binding domain thereof, transgenic plants and plant cells transformed with the polynucleotides. The invention further relates to methods of transforming plants and plant cells with cellulose synthase or UDP-encoding polynucleotides.

The invention relates to a method for continuously detecting the glucose concentration in a sample, a reagent kit and a method for using a biosensor. The method for continuously detecting the glucose concentration in the sample comprises the following steps of: (a) providing the biosensor, wherein the biosensor comprises a converter and polysaccharide covering on the surface of the converter; (b) providing a carbohydrate-binding protein solution with specific concentration, wherein carbohydrate-binding protein is at least provided with a receptor, and the receptor has the capability of being combined with carbohydrate and glucose; (c) mixing the sample to be detected and the carbohydrate-binding protein solution with the specific concentration into a mixture; (d) contacting the mixture with the biosensor; (e) detecting the quantity of the carbohydrate-binding protein combined with the carbohydrate through the biosensor, wherein the glucose concentration of the sample to be detected and the quantity of the carbohydrate-binding protein combined with the carbohydrate form an inverse relation; and (f) recovering the surface of the biosensor through a high-concentration glucose solution.

The invention relates to a drug composition for hyperphosphatemia and a preparation method of the drug composition. The drug composition, as chewable tablets, comprises 477-954g of lanthanum carbonate hydrate, 5-10g of polylactic acid, 500-1000g of dextrates, 20-40g of colloidal silicon dioxide and 10-20g of magnesium stearate.

A two-chain insulin analogue contains an A chain modified by (i) a monomeric glucose-binding element at or near its N terminus and (ii) a B chain modified by at or near its C terminus by an element that reversibly binds to the monomeric glucose-binding element such that this linkage is displaceable by glucose. The monomeric glucose-binding element may be phenylboronic acid derivative (optionally halogenated). The B chain may be modified by a diol-containing element derived from a monosaccharide, disaccharide or oligosaccharide, a non-saccharide diol-containing moiety or a α-hydroxycarboxylate-containing moiety. The analogue can be manufactured by trypsin-mediated semi-synthesis. Formulations can be at strengths U-10 to U-1000 in soluble solutions at pH 7.0-8.0 with or without zinc ions at a molar ratio of 0.0-3.0 ions per insulin analogue monomer. A patient with diabetes mellitus may be treated with subcutaneous, intraperitoneal, or oral administration of a physiologically effective amount of the insulin analogue.

Belonging to the technical field of refractory material preparation, the invention relates to a preparation method of a glucose combined magnesia carbon brick. The method adopts magnesite (fused magnesite or sintered magnesite) and a carbon raw material (flake graphite, carbon black or electrode chip) as the main raw materials, glucose is added as a binding agent and other additives are added, and by means of compounding, mixing, aging, molding, drying and other technological processes are carried out to obtain a non-fired magnesia carbon brick. The refractory material provides low temperature strength through the glucose binding agent, and the glucose binding agent undergoes thermal decomposition and carbonization to form a carbon structure so as to provide medium and high temperature strength. Compared with the traditional phenolic resin combined magnesia carbon brick, the glucose combined magnesia carbon brick has the advantages of environmental friendliness and low cost. The preparation method also provides the technical and theoretical basis for application of glucose binding agent to other high-temperature resistant materials.

Disclosed herein is a glucose-responsive insulin delivery system based on the interaction between the glucose-modified insulin and glucose transporters (GLUTs) on erythrocytes (or red blood cells, RBCs). After being conjugated with glucose, insulin can efficiently bind to RBC membranes. The binding is reversible in the setting of hyperglycemia, resulting in fast release of insulin and subsequent drop of blood glucose (BG) level in vivo. In some embodiments, the delivery vehicle can include: 1) intravenously injectable polymeric nanoparticles (˜100 nm in diameter) coated with RBC membrane and loaded with glucose-modified insulin and/or 2) painless microneedle (MN) patches loaded with the complex of GLUT and glucose-modified insulin.